Clinical Trials
25
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
- Conditions
- Iron Overload Due to Repeated Red Blood Cell Transfusions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 30
- Registration Number
- NCT03802916
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States
🇨🇦St.Paul's Hospital, Vancouver, British Columbia, Canada
Study of Parkinson's Early Stage With Deferiprone
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 140
- Registration Number
- NCT02728843
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇫🇷CHU de Bordeaux, Centre Expert Parkinson, Bordeaux, France
🇫🇷Hôpital Henri Mondor, Creteil, France
Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 20
- Registration Number
- NCT02465489
- Locations
- 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada
Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects
- Conditions
- Asymptomatic HIV Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 30
- Registration Number
- NCT02456558
- Locations
- 🇿🇦
Phoenix Pharma, Port Elizabeth, Eastern Cape, South Africa
🇿🇦VxPharma, Pretoria, South Africa
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
- Conditions
- Iron OverloadSickle Cell DiseaseOther Anemias
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 134
- Registration Number
- NCT02443545
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Children's Hospital of Michigan, Detroit, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next